| pubmed-article:2985093 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:2985093 | lifeskim:mentions | umls-concept:C0728866 | lld:lifeskim |
| pubmed-article:2985093 | lifeskim:mentions | umls-concept:C0002771 | lld:lifeskim |
| pubmed-article:2985093 | lifeskim:mentions | umls-concept:C0060583 | lld:lifeskim |
| pubmed-article:2985093 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:2985093 | pubmed:dateCreated | 1985-5-16 | lld:pubmed |
| pubmed-article:2985093 | pubmed:abstractText | The analgesic potency of ethyl-N-[2-amino-6-(4-fluorophenylmethylamino)pyridin-3-yl]carb ama te (flupirtine, D 9998) in mice and rats in Haffner's test, electro-pain test and Randall-Selitto test (inflammation induced pain) lies between the more potent dextromoramide and methadone and the more weakly active pethidine, dextropropoxyphene, codeine, phenacetin and paracetamol. In comparison to codeine flupirtine is up to 4 times more potent, up to 2 times more active than pethidine and 4 times more potent than dextropropoxyphene in the above-mentioned methods. With one exception of inflammation induced pain, where flupirtine shows an activity of about 1 1/2 times that of phenacetin and paracetamol, both analgesics are about 10 to nearly 30 times less active than flupirtine in other above-mentioned tests. In the hot plate test flupirtine is twice as active as codeine and approximately 10 times more active than phenacetin and paracetamol. The weakest analgesic activity of flupirtine is seen in acetic acid test where it is about half as active as codein and approximately as active as dextropropoxyphene. Nevertheless, flupirtine is up to 10 times more potent than phenacetin and paracetamol. The acetic acid test is claimed to be non-specific according to our own experience and to other authors. Flupirtine is enterally absorbed at a higher degree than the other tested centrally acting analgesics. In regard to the results of various analgesic investigations in mice and rats flupirtine can be classified as a medium to strong acting analgesic. The duration of action of flupirtine is comparable to that of codeine. Experiments with flupirtine suggest that there are some convincing criteria for a pronounced central acting component of its analgesic activity. These criteria are the strong efficacy in the hot-plate and Haffner's test, in which only centrally acting analgesics show distinct effects, and the finding that flupirtine increases the pain threshold for vocalisation in rats and mice excluding a pure reflex of the spinal cord. In current experiments concerning the mode of action flupirtine exhibits a distinct central analgesic component of action. In spite of its relatively high analgesic potency which corresponds to that of opiates flupirtine does not show any other signs of opiate properties and other potent analgesics. Thus, flupirtine does not develop tolerance in mice and rats after 19 or 17 days of daily administration.(ABSTRACT TRUNCATED AT 400 WORDS) | lld:pubmed |
| pubmed-article:2985093 | pubmed:language | ger | lld:pubmed |
| pubmed-article:2985093 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2985093 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:2985093 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2985093 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2985093 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2985093 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2985093 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2985093 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2985093 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2985093 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:2985093 | pubmed:issn | 0004-4172 | lld:pubmed |
| pubmed-article:2985093 | pubmed:author | pubmed-author:ThiemerKK | lld:pubmed |
| pubmed-article:2985093 | pubmed:author | pubmed-author:SofiaR DRD | lld:pubmed |
| pubmed-article:2985093 | pubmed:author | pubmed-author:JakovlevVV | lld:pubmed |
| pubmed-article:2985093 | pubmed:author | pubmed-author:von... | lld:pubmed |
| pubmed-article:2985093 | pubmed:author | pubmed-author:Achterrath-Tu... | lld:pubmed |
| pubmed-article:2985093 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:2985093 | pubmed:volume | 35 | lld:pubmed |
| pubmed-article:2985093 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:2985093 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:2985093 | pubmed:pagination | 30-43 | lld:pubmed |
| pubmed-article:2985093 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:2985093 | pubmed:meshHeading | pubmed-meshheading:2985093-... | lld:pubmed |
| pubmed-article:2985093 | pubmed:meshHeading | pubmed-meshheading:2985093-... | lld:pubmed |
| pubmed-article:2985093 | pubmed:meshHeading | pubmed-meshheading:2985093-... | lld:pubmed |
| pubmed-article:2985093 | pubmed:meshHeading | pubmed-meshheading:2985093-... | lld:pubmed |
| pubmed-article:2985093 | pubmed:meshHeading | pubmed-meshheading:2985093-... | lld:pubmed |
| pubmed-article:2985093 | pubmed:meshHeading | pubmed-meshheading:2985093-... | lld:pubmed |
| pubmed-article:2985093 | pubmed:meshHeading | pubmed-meshheading:2985093-... | lld:pubmed |
| pubmed-article:2985093 | pubmed:meshHeading | pubmed-meshheading:2985093-... | lld:pubmed |
| pubmed-article:2985093 | pubmed:meshHeading | pubmed-meshheading:2985093-... | lld:pubmed |
| pubmed-article:2985093 | pubmed:meshHeading | pubmed-meshheading:2985093-... | lld:pubmed |
| pubmed-article:2985093 | pubmed:meshHeading | pubmed-meshheading:2985093-... | lld:pubmed |
| pubmed-article:2985093 | pubmed:meshHeading | pubmed-meshheading:2985093-... | lld:pubmed |
| pubmed-article:2985093 | pubmed:meshHeading | pubmed-meshheading:2985093-... | lld:pubmed |
| pubmed-article:2985093 | pubmed:meshHeading | pubmed-meshheading:2985093-... | lld:pubmed |
| pubmed-article:2985093 | pubmed:meshHeading | pubmed-meshheading:2985093-... | lld:pubmed |
| pubmed-article:2985093 | pubmed:meshHeading | pubmed-meshheading:2985093-... | lld:pubmed |
| pubmed-article:2985093 | pubmed:meshHeading | pubmed-meshheading:2985093-... | lld:pubmed |
| pubmed-article:2985093 | pubmed:meshHeading | pubmed-meshheading:2985093-... | lld:pubmed |
| pubmed-article:2985093 | pubmed:year | 1985 | lld:pubmed |
| pubmed-article:2985093 | pubmed:articleTitle | [The pharmacologic effect of flupirtine, a structurally new analgesic]. | lld:pubmed |
| pubmed-article:2985093 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:2985093 | pubmed:publicationType | In Vitro | lld:pubmed |
| pubmed-article:2985093 | pubmed:publicationType | English Abstract | lld:pubmed |
